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Abstract
Background: To date, no system has been published that allows investigators to adjust for the
overall sedative and/or analgesic effects of medications, or changes in medications, in clinical trial
participants for whom medication use cannot be controlled. This is common in clinical trials of
behavioral and complementary/alternative therapies, and in research involving elderly or chronically
ill patients for whom ongoing medical care continues during the trial. This paper describes the
development, and illustrates the use, of a method we developed to address this issue, in which we
generate single continuous variables to represent the daily sedative and analgesic loads of multiple
medications.
Methods: Medications for 90 study participants in a clinical trial of a nonpharmacological
intervention were abstracted from medication administration records across multiple treatment
periods. An expert panel of three academic clinical pharmacists and a geriatrician met to develop a
system by which each study medication could be assigned a sedative and analgesic effect rating.
Results: The two measures, when applied to data on 90 institutionalized persons with Alzheimer's
disease, resulted in variables with moderately skewed distributions that are consistent with the clinical
profile of analgesia and sedation use in long-term care populations. The average study participant
received 1.89 analgesic medications per day and had a daily analgesic load of 2.96; the corresponding
figures for sedation were 2.07 daily medications and an average daily load of 11.41.
Conclusions: A system of classifying the sedative and analgesic effects of non-study medications
was created that divides drugs into categories based on the strength of their effects and assigns a
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rating to express overall sedative and analgesic effects. These variables may be useful in comparing
patients and populations, and to control for drug effects in future studies.
Keywords
medication; sedative; analgesic; coding; long-term care
Introduction
Early studies of the efficacy and safety of treatments (phase 2 clinical trials) generally control
for patient-related factors, such as non-study medications, by holding them constant during the
study period. However, the majority of clinical research studies that involve longitudinal data
collection -- including many phase 3 clinical trials and virtually all broader effectiveness studies
(phase 4 trials; Type 2 translational research) -- are unable to hold all other patient treatments
constant during a study period [1]. This problem occurs frequently in studies involving older
persons, who often have multiple comorbid conditions, requiring multiple medications, for
which treatment changes must occur even while enrolled in a clinical trial. This is also often
the case in studies conducted in community settings, where patients may seek alternative
medical treatments even while enrolled in a study. It is a particularly challenging issue when
the outcome of interest is pain relief, sleep, or alertness, since many medications possess
analgesic or sedative properties. Therefore, valid methods need to be available to control for
changes in non-study medications that occur during data collection.
Since the 1970s, the World Health Organization (WHO) has developed, maintained, and
updated a system that classifies drugs into categories, the anatomical therapeutic chemical
(ATC) classification system [2]. Within that system, the relative potency of drugs is classified
using the defined daily dose (DDD) however, this system does not classify the side effect
potential of drugs, which often does not parallel the DDD. Therefore, an alternative method is
needed to classify the sedative and analgesic effects of medications.
A few systems have been published that have attempted to classify sedative and analgesic drug
effects. A method of classifying drugs based on their sedative properties was described by
Linjakumpu, et al [3], who applied it to a descriptive study of home-dwelling older adults. That
system divides all drugs into four categories: primary sedatives and psychotropics (Group 1),
drugs with sedation as a prominent side effect or preparations with a sedating component
(Group 2), drugs with sedation as a potential adverse effect (Group 3), and drugs with no known
sedation (Group 4). The most prominent system for classifying relative analgesic potency is
the WHO Analgesic Ladder [4], which is intended more as a broad set of principles than as a
rigid framework. The three categories of the WHO Analgesic Ladder are: a non-opioid
analgesic, with or without an adjuvant agent (step 1), an opioid for mild to moderate pain, often
in combination with one or more step 1 medications (step 2), and an opioid for moderate to
severe pain, with or without step 1 medications (step 3). No report has, however addressed
how to use such a system in research, and, in particular, how to account for multiple medications
in a single patient or medication changes over time.
Our research group has been involved in the analysis of data from several therapeutic trials of
nonpharmacological agents in persons with Alzheimer's disease, in which the need arose to
control for differences and changes in non-study medications that occurred during the study
period. We were unable to find a suitable method in the literature, and, therefore, sought to
develop and pilot test a classification system that would allow us to represent, as single
continuous variables, the estimated total sedative effect and total analgesic load of all
medications taken. In developing the system, we sought to: (a) accurately reflect the relative
effect of each medication, and (b) allow patients with multiple medications to have the effects
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summed. This paper describes the system we developed and illustrates its application, using
data from a National Institutes of Health-funded clinical trial of the effect of high intensity
light therapy on sleep, depression, and other behavioral symptoms in older persons residing in
two geriatric care facilities.
Methods
Medications for all study participants were abstracted from the medication administration
records for each data collection period. The following information was recorded on each
medication received at least once during the data collection period: name, dosage received at
each administration time, frequency of administration, start date, and stop date (if applicable).
Both scheduled and “as needed” (i.e., pro re nata [PRN]) medications were recorded. A single
pharmacist (JI) reviewed these records to ensure that medication names were spelled correctly
and that different brand names corresponding to the same generic drug were recorded as the
generic name.
Next, an expert panel of three academic clinical pharmacists (JI, MR, and MR) and a
geriatrician (PS) met to develop a system in which each study medication could be assigned a
sedative and analgesic effect rating. Each drug received by any participant in either study was
reviewed to determine sedative and analgesic effects, to classify it, and to assign a “standard”
dose. In categorizing drugs, determining relative effects, and assigning a standard dose to each
medication, the expert panel relied on existing literature and their clinical experience.
Sedation ratings were assigned based on a modification of the sedation systematic classification
method formulated by Linjakumpu and colleagues [3]. Drugs with sedation as a primary action
or side effect were divided into four groups based on a modification of the Anatomical
Therapeutic Chemical Classification system (ATC) [5]. Medications that were not specifically
included in either of the above classification systems were given a sedation rating based on
their pharmacological properties, indication, and therapeutic similarity to other drugs in the
respective 4 groups. The groups were then assigned relative potency ratings, based on the team's
consensus of the effects of one group vis-à-vis the other, and the cumulative effects of using
multiple agents. The four groups are described below:
• Sedation group 1 consists of psychotropic agents whose primary effect is sedation.
Medications in Group 1 were given a sedation potency rating of 6.
• Sedation group 2 includes drugs with sedation as a prominent side effect or
preparations with a strong sedating component. Medications in Group 2 were assigned
a sedation rating of 3.
• Sedation group 3 includes drugs with sedation as a potential adverse effect that can
persist beyond initiation of the drug. Medications in group 3 were given a sedation
rating of 1.
• Sedation group 4 consists of drugs with no known sedation. Medications in group 4
were given a sedation rating of 0.
Analgesic ratings were assigned using a modification of the WHO Analgesic Ladder [4], and
the American Pain Society's principles of analgesia [6]. Based on these and other reference
texts [7,4,6,8], all medications within the study were grouped as opioids for the treatment of
moderate to severe pain, opioids for the treatment of mild to moderate pain, non-opioid
analgesics, adjuvant (co-analgesic) medications, or nonanalgesic agents (drugs without
analgesic or adjuvant properties). The groups were then assigned relative potency ratings, based
on the team's consensus of the effects of one group vis-à-vis the other, and the cumulative
effects of using multiple agents. Each group is described below:
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• Opioids for the treatment of moderate to severe pain. Opioids (or medications with
similar effectiveness) whose potency was equal to or greater than morphine on a
milligram-to-milligram basis are in this category. Drugs in this category were
assigned an analgesic potency rating of 9.
• Opioids for the treatment of mild to moderate pain. Opioids (or medications with
similar effectiveness) whose common dosage range is less potent than that of
morphine are in this category. Drugs in this category were assigned an analgesic
potency rating of 6.
• Non-opioid analgesics. These are non-opioid medications that are used primarily for
the treatment of pain. Drugs in this category were assigned an analgesic potency rating
of 3.
• Adjuvant, or co-analgesic medications. These are drugs with independent analgesic
properties in certain situations or the ability to enhance the effects of opioids or non-
opioid analgesics. Drugs in this category were assigned an analgesic potency rating
of 1.
• Nonanalgesic agents, or drugs without analgesic or adjuvant properties. These were
assigned an analgesic potency rating of zero (0).
For all medications assigned a non-zero value for sedation and/or analgesia, resident
medication records were further abstracted to produce a daily record of the amount received
of each drug for each resident. For each resident for each day, the sedative load (SLij, for
resident i on day j) was then computed according to the following formula:
where
- m is the number of sedative medications for resident i on day j
- Doseijk is the quantity of medication k received by resident i on day j (in same units as
ADMDk)
- SRk is the sedation rating (1, 3, 6) for sedating medication k
- ADMDk is the average daily maintenance dose for medication k
For residents not receiving any sedative medications on a given day, a value of 0 was assigned.
The daily analgesic load for each resident (ALij) was computed in the same way, using the
analgesic rating (1, 3, 6, 9) for each analgesic medicine (ARk). For analyses in which the
sedative and analgesic loads were needed at a higher level of summarization than the resident-
day (e.g. for the resident-study period), then the daily load scores were averaged over the days
in the period. This resulted in a single continuous variable for each study participant and each
data collection period. This variable was then used in longitudinal analyses to control for
changes in medications at the resident level across the data collection period.
To illustrate how this system was used in analysis of clinical trial data, we present data from
our study of a light therapy intervention in two long-term care facilities. That study
systematically altered the intensity and timing of lighting in public areas during a series of 3-
week study periods, and effects on the sleep and activity pattern of study participants were
evaluated. Details of the study design are published elsewhere [9]. Summary statistics for
number of daily analgesic medications, daily analgesic load, number of daily sedative
medications, and daily sedative load were computed. In order to account for the lack of
independence among the multiple daily records for each resident, a two-step procedure was
used to compute these summary statistics. First, a resident-level average was generated as the
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mean across all observations (days) for a given resident. Second, summary statistics (mean,
standard deviation, quantiles) were computed based on these resident-level means.
In order to assess the validity of the analgesic and sedative rating system, we compared the
medication scores according to selected participant characteristics for which we might expect
variation in use of these medications. These characteristics included site, gender, whether or
not the participant had dementia, and if demented, the severity of dementia as rated by the
Minimum Data Set Cognition Scale (MDS-COGS), a staff-rated measure of cognitive function
[10]. Participants were also categorized with respect to level of agitation and daytime sleepiness
during each three-week study period. Agitated behavior was measured using the short form of
the Cohen-Mansfield Agitation Inventory [11], which was reported for each resident by
caregiving staff on each shift for each study period. Daytime drowsiness was measured using
direct observation by research staff, who conducted up to 48 randomly distributed one-minute
observations of each participant during the last seven days of each study period, using a
modification of the Resident and Staff Observation Instrument [12]; for each participant the
proportion of observations for the given study period during which he or she was coded as
asleep or drowsy was computed. For purposes of comparison of medication use, agitation
scores and daytime drowsiness were dichotomized at the median.
Means of the medication measures were computed across all observations (days) overall, and
according to the specified resident characteristics; the standard errors of the means were
adjusted for the repeated measures on study participants using Taylor series expansion methods
[13]. For the purposes of testing whether the medication measures differed significantly
according to the selected participant characteristics, linear mixed models were used for each
medication measure and each characteristic, specifying the medication measure as the
dependent variable, the given participant characteristic as a single fixed effect and including a
random effect for participant [14]. The results are displayed in Table 4.
Results
The study gathered data on 90 participants from two sites – a geropsychiatric hospital and a
dementia-specific assisted living facility. The 90 study participants participated in a total of
432 three-week study periods, for a total of 9,072 daily records of sedative and analgesic loads.
A total of 60 different sedative medications and 46 analgesic medications were received by the
90 study participants (Tables 1 and 2). Among the sedative medications, lorazepam was the
most commonly prescribed Group 1 drug; olanzapine and risperidone were the most commonly
prescribed Group 2 drugs; and donepezil, atenolol, clonidine, levodopa, doxazosin, terazosin,
and prazosin were the only prescribed group 3 drugs. Among the analgesic medications in our
study data, morphine and methadone were the only prescribed opioids for moderate-to-severe
pain, the most common opioid in the mild-to-moderate pain category was hydrocodone; the
most common non-opioid analgesics were aspirin, acetaminophen, and ibuprofen; and the most
common adjuvant or co-analgesic medications were lorazepam and sertraline.
Descriptive statistics on the analgesia and sedation summary variables are displayed in Table
3. The average study participant received 1.89 analgesic medications per day and had a daily
analgesic load of 2.91; the corresponding figures for sedation were 2.07 daily medications and
an average daily load of 11.49.
Table 4 displays the mean scores for the analgesic daily load and the sedative daily load, by
site, participant gender, dementia status, agitation level, and daytime drowsiness. For
comparison purposes, the mean number of analgesic or sedative medications is also displayed.
Statistical comparisons indicate, that in these data, differences between all dichotomized
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variables were statistically significant at p<.001, with the only exception being gender and
sedative load.
Discussion
Classifying sedative and analgesic medications in a manner that allows investigators to
compare individuals across time periods and across studies is a challenging issue in the design
and analysis of clinical trials. This paper describes a method whereby, based on the existing
literature on the comparative effects of medications and a consensus-development process
involving three clinical pharmacists and a geriatrician, drugs were categorized in a manner that
enabled a clinical trial to represent sedation and analgesia as single continuous variables. The
two measures, when applied to data from a study of 90 institutionalized persons with
Alzheimer's disease, resulted in variables with moderately skewed distributions (Table 3) that
are consistent with the clinical profile of analgesia and sedation use in a long-term care
population, and that yielded statistically significant associations in bivariate analyses using
selected participant characteristics for which variation in medication use could be expected
(Table 4).
Such a method will, if validated by further use, have several advantages. It will facilitate the
comparison across studies of the amount of analgesia and sedation received by specific
populations and samples. More importantly, it will for the first time allow investigators to
incorporate the relative potencies of medications into a single continuous variable. Because its
method is based on general principles, it can be used by other investigators with different patient
populations and can accommodate changing trends in medication use.
There are, of course, limitations to this method. Assignment of drugs to categories, of relative
potencies to each category, and the resultant summation formula are derived based on the
literature and expert consensus, rather than on physiological studies. However, given the vast
array of drugs currently marketed and the absence of head-to-head comparisons, this method
was the only one available to the study team. Such a system does, of course result in some
decisions that could be debated. In spite of these limitations, we believe that this method
constitutes a considerable improvement over previous strategies used to accommodate for
medication effects.
Further validation will be critical to determining the usefulness of this methodology and, if
necessary, in making modifications. Among the validation approaches that could be considered
in future studies include: confirmation of face validity through a more formal consensus process
with a multidisciplinary panel; criterion validation of the absolute values assigned to categories
or category combinations through comparison with, for example, self-ratings of pain or
drowsiness by volunteers to whom various sample medications and medication combinations
are administered; concurrent validation through comparison with caregiver self-report of
sedation or analgesia; and convergent validation through use of the instrument in multiple
studies.
In conclusion, we have developed, and successfully used in the analyses of clinical trial data,
a method of classifying the sedative and analgesic effects of non-study medications. Our
method divides all drugs into categories based on the relative strength of their effects and
generates a continuous variable expressing sedation load and another expressing analgesic
load. These variables can then be applied to describe and compare participants and populations,
to compute change over time in longitudinal studies, and to control for drug effects in studies
where drug effects could confound the primary relationship being studied.
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Table 1














3 1 DONEPEZIL 25 1,739
3 1 ATENOLOL 6 729
3 1 CLONIDINE 5 791
3 1 LEVODOPA 3 151
3 1 DOXAZOSIN 2 378
3 1 TERAZOSIN 2 291
3 1 PRAZOSIN 2 280
2 3 OLANZAPINE 25 1,962
2 3 RISPERIDONE 23 1,514
2 3 SERTRALINE 21 1,144
2 3 QUETIAPINE 16 1,232
2 3 TRAZODONE 15 996
2 3 HALOPERIDOL 13 548
2 3 VALPROIC ACID 11 866
2 3 MIRTAZAPINE 9 593
2 3 ESCITALOPRAM 6 895
2 3 CITALOPRAM 6 548
2 3 VENLAFAXINE 5 391
2 3 PHENYTOIN 4 659
2 3 PAROXETINE 5 344
2 3 BUPROPION 5 158
2 3 BENZTROPINE 4 517
2 3 HYDROCODONE 4 128
2 3 GABAPENTIN 3 389
2 3 OXCARBAZEPINE 3 300
2 3 TOPIRAMATE 3 179
2 3 PROPOXYPHENE 3 168
2 3 METOCLOPRAMIDE 2 82
2 3 DIVALPROATE 2 26
2 3 INDOMETHACIN 2 19
2 3 ARIPIPRAZOLE 2 17
2 3 MORPHINE 2 14
2 3 PROMETHAZINE 2 2
2 3 CARBAMAZEPINE 1 168
2 3 TRAMADOL 1 168
2 3 VALPROATE 1 168
2 3 METHADONE 1 104
2 3 DEXTROMETHORPHAN 1 15
2 3 FLUOXETINE 1 15
2 3 CHLORPROMAZINE 1 6
2 3 PERGOLIDE 1 4
2 3 DOXEPIN 1 3
2 3 HYDROXYZINE 1 2
2 3 ATROPINE 1 1
2 3 DIPHENOXYLATE 1 1
2 3 FOSPHENYTOIN 1 1
1 6 LORAZEPAM 43 1,337
1 6 CLONAZEPAM 6 340
1 6 CHLORAL HYDRATE 5 92
1 6 DIPHENHYDRAMINE 2 209
1 6 CHLORDIAZEPOXIDE 2 189
1 6 ZOLPIDEM 2 53
1 6 DIAZEPAM 2 42
1 6 ZALEPLON 1 168
1 6 CLORAZEPATE 1 105
1 6 TEMAZEPAM 1 55
1 6 ALPRAZOLAM 1 41
1 6 PHENELZINE 1 12
1 6 MOLINDONE 1 9
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Table 2
Listing of all Analgesic Medications Received by Study Participants, by Analgesic Potency Rating Category













Adjuvant 1 LORAZEPAM 43 1,337
Adjuvant 1 SERTRALINE 21 1,144
Adjuvant 1 TRAZODONE 15 996
Adjuvant 1 VALPROIC ACID 11 866
Adjuvant 1 MIRTAZAPINE 9 593
Adjuvant 1 ESCITALOPRAM 6 895
Adjuvant 1 CITALOPRAM 6 548
Adjuvant 1 CLONAZEPAM 6 340
Adjuvant 1 CLONIDINE 5 791
Adjuvant 1 DILTIAZEM 5 648
Adjuvant 1 VENLAFAXINE 5 391
Adjuvant 1 PAROXETINE 5 344
Adjuvant 1 CHLORAL HYDRATE 5 92
Adjuvant 1 OXCARBAZEPINE 3 300
Adjuvant 1 CHLORDIAZEPOXIDE 2 189
Adjuvant 1 PREDNISONE 2 69
Adjuvant 1 PHENAZOPYRIDINE 2 45
Adjuvant 1 DIVALPROATE 2 26
Adjuvant 1 PROMETHAZINE 2 2
Adjuvant 1 CARBAMAZEPINE 1 168
Adjuvant 1 VALPROATE 1 168
Adjuvant 1 ZALEPLON 1 168
Adjuvant 1 CLORAZEPATE 1 105
Adjuvant 1 TEMAZEPAM 1 55
Adjuvant 1 ALPRAZOLAM 1 41
Adjuvant 1 FLUOXETINE 1 15
Adjuvant 1 CHLORPROMAZINE 1 6
Adjuvant 1 DOXEPIN 1 3
Adjuvant 1 HYDROXYZINE 1 2
Adjuvant 1 DIPHENOXYLATE 1 1
Non-opioid 3 ASPIRIN 55 4,418
Non-opioid 3 ACETAMINOPHEN 44 2,076
Non-opioid 3 IBUPROFEN 21 1,225
Non-opioid 3 ROFECOXIB 4 64
Non-opioid 3 GABAPENTIN 3 389
Non-opioid 3 PROPOXYPHENE 3 168
Non-opioid 3 SALSALATE 2 105
Non-opioid 3 INDOMETHACIN 2 19
Non-opioid 3 VALDECOXIB 1 123
Non-opioid 3 NABUMETONE 1 18
Non-opioid 3 CELECOXIB 1 4
Opioid, mild/mod 6 HYDROCODONE 4 128
Opioid, mild/mod 6 TRAMADOL 1 168
Opioid, modsevere 9 MORPHINE 2 14
Opioid, mod/severe 9 METHADONE 1 104
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